US equities
|
TSLA
$394.58
▲+6.01%
MU
$911.73
▲+3.89%
NVDA
$216.57
▲+2.66%
SPCX
$148.57
▲+0.73%
META
$634.38
▼-1.28%
AAPL
$343.22
▼-1.29%
SNDK
$1,265.69
▲+2.23%
INTC
$91.72
▲+5.48%
TSLA
$394.58
▲+6.01%
MU
$911.73
▲+3.89%
NVDA
$216.57
▲+2.66%
SPCX
$148.57
▲+0.73%
META
$634.38
▼-1.28%
AAPL
$343.22
▼-1.29%
SNDK
$1,265.69
▲+2.23%
INTC
$91.72
▲+5.48%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Tevogen Inc. - Common Stock
(NQ:
TVGN
)
6.350
-0.180 (-2.76%)
Delayed Quote
Updated: 3:11 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tevogen Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
April 29, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
April 29, 2025
Via
Benzinga
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
↗
April 29, 2025
Via
Benzinga
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
April 29, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Monday?
↗
April 28, 2025
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On?
↗
April 28, 2025
Tevogen Bio Holdings shares are ripping higher in Monday's after-hours session after the company reaffirmed its oncology pipeline revenue forecast.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
April 28, 2025
Via
Benzinga
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
April 28, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Announces 2025 Annual Meeting
April 25, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility
April 17, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
April 15, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
April 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States
April 09, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
April 08, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission
April 07, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
March 26, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
March 25, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
March 10, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
March 07, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential
↗
March 04, 2025
D Boral Capital initiates Buy on Tevogen Bio citing its scalable T-cell therapies and upcoming clinical readouts, with a $10 price target.
Via
Benzinga
This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
March 04, 2025
Via
Benzinga
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
March 03, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
February 28, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
February 21, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
February 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
February 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
February 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
February 13, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
February 10, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
February 07, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
